CELON PHARMA S.A. ZY-10
Celon Pharma S.A., an integrated pharmaceutical company, engages in the research, manufacture, and marketing of pharmaceutical products and preparations. It offers drugs to treat cancers, neurological diseases, diabetes, and other metabolic disorders. The company was founded in 2002 and is based in Lomianki, Poland. Celon Pharma S.A. operates as a subsidiary of Glatton Sp. z o.o.
Market Cap & Net Worth: CELON PHARMA S.A. ZY-10 (8RP)
CELON PHARMA S.A. ZY-10 (F:8RP) has a market capitalization of $285.81 Million (€278.44 Million) as of March 18, 2026. Listed on the F stock exchange, this Germany-based company holds position #17226 globally and #1792 in its home market, demonstrating a 7.37% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying CELON PHARMA S.A. ZY-10's stock price €5.17 by its total outstanding shares 53856500 (53.86 Million).
CELON PHARMA S.A. ZY-10 Market Cap History: 2021 to 2026
CELON PHARMA S.A. ZY-10's market capitalization history from 2021 to 2026. Data shows change from $330.86 Million to $285.81 Million (-9.35% CAGR).
CELON PHARMA S.A. ZY-10 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how CELON PHARMA S.A. ZY-10's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 8RP by Market Capitalization
Companies near CELON PHARMA S.A. ZY-10 in the global market cap rankings as of March 18, 2026.
Key companies related to CELON PHARMA S.A. ZY-10 by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #423 globally with a market cap of $51.97 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #455 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #719 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #423 | Zoetis Inc | NYSE:ZTS | $51.97 Billion | $118.15 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.46 |
| #455 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #719 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
CELON PHARMA S.A. ZY-10 Historical Marketcap From 2021 to 2026
Between 2021 and today, CELON PHARMA S.A. ZY-10's market cap moved from $330.86 Million to $ 285.81 Million, with a yearly change of -9.35%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €285.81 Million | +15.14% |
| 2025 | €248.22 Million | -23.51% |
| 2024 | €324.51 Million | +72.91% |
| 2023 | €187.67 Million | +20.03% |
| 2022 | €156.36 Million | -52.74% |
| 2021 | €330.86 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of CELON PHARMA S.A. ZY-10 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $285.81 Million USD |
| MoneyControl | $285.81 Million USD |
| MarketWatch | $285.81 Million USD |
| marketcap.company | $285.81 Million USD |
| Reuters | $285.81 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.